The international consortium on lithium genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment

Neuropsychobiology

Volumn 62, Issue 1, 2010, Pages 72-78

  Schulze, Thomas G ^a,f,ad   Alda, Martin ^l,ad   Adli, Mazda ^g,ad   Akula, Nirmala ^a   Ardau, Raffaella ^s   Bui, Elise T ^a   Chillotti, Caterina ^s   Cichon, Sven ^h,ae   Czerski, Piotr ^u   Del Zompo, Maria ^s,t   Detera Wadleigh, Sevilla D ^a   Grof, Paul ^m,n,ad   Gruber, Oliver ⁱ   Hashimoto, Ryota ^w,ac   Hauser, Joanna ^u   Hoban, Rebecca ^b,c   Iwata, Nakao ^x,ac   Kassem, Layla ^a   Kato, Tadafumi ^y,ac   Kittel Schneider, Sarah ^j   Kliwicki, Sebastian ^v   Kelsoe, John R ^b,c   Kusumi, Ichiro ^aa,ac   Laje, Gonzalo ^a   Leckband, Susan G ^b,c,d   Manchia, Mirko ^t   MacQueen, Glenda ^o   Masui, Takuya ^aa,ac   Ozaki, Norio ^ab,ac   Perlis, Roy H ^e   Pfennig, Andrea ^k,ad   Piccardi, Paola ^t   Richardson, Sara ^a   Rouleau, Guy ^p   Reif, Andreas ^j   Rybakowski, Janusz K ^v,ad   Sasse, Johanna ^k,ad   Schumacher, Johannes ^a,h   Severino, Giovanni ^t   Smoller, Jordan W ^e   Squassina, Alessio ^t   Turecki, Gustavo ^q   Young, L Trevor ^r,ad   Yoshikawa, Takeo ^z,ac   Bauer, Michael ^k,ad   McMahon, Francis J ^a   more..

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF BONN   (Germany)

ⁱ UNIVERSITY OF GÖTTINGEN   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l DALHOUSIE UNIVERSITY   (Canada)

^m Mood Disorders Centre of Ottawa   (Canada)

ⁿ UNIVERSITY OF TORONTO   (Canada)

^o UNIVERSITY OF CALGARY   (Canada)

^p UNIVERSITÉ DE MONTRÉAL   (Canada)

^q MCGILL UNIVERSITY   (Canada)

^r UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^s Hospital University Agency   (Canada)

^t UNIVERSITY OF CAGLIARI   (Italy)

^u Psychiatric Genetic Unit   (Italy)

^v POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^w OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^x FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^y Laboratory for Molecular Dynamics of Mental Disorders   (Japan)

^z RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^aa HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ab NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ac Japanese Collaborative Group on the Genetics of Lithium Response in Bipolar Disorder   (Japan)

^ad International Group for the Study of Lithium Treated Patients (IGSLI)   (Japan)

^ae FORSCHUNGSZENTRUM JÜLICH   (Germany)

more..

Author keywords

Antidepressants; Genome wide association study; Manic depressive illness; Mood stabilizer; Neurogenesis; Neuroplasticity; Schizoaffective disorder; Suicidal behavior

Indexed keywords

ANTIDEPRESSANT AGENT; DIACYLGLYCEROL KINASE; LITHIUM SALT; PHOSPHATIDYLINOSITOL; WNT PROTEIN; LITHIUM DERIVATIVE; TRANQUILIZER;

BIPOLAR DISORDER; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR DEPRESSION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; GENETICS; INTERNATIONAL COOPERATION; NATIONAL HEALTH ORGANIZATION; UNITED STATES;

ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; INTERNATIONAL COOPERATION; LITHIUM COMPOUNDS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PHARMACOGENETICS; PHENOTYPE; UNITED STATES;

EID: 77951941717     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314708     Document Type: Review

References (30)

1. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, Guchelaar HJ: Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007; 4:e209.
2. Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, Wadelius C, Melhus H: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004; 4: 40-48.
3. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
4. Penny MA, McHale D: Pharmacogenomics and the drug discovery pipeline: when should it be implemented? Am J Pharmacogenomics 2005; 5: 53-62.
5. Roses AD: Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008; 7: 807-817.
6. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ: Background and rationale for the sequenced treatment alternatives to relieve depression (STAR * D) study. Psychiatr Clin North Am 2003; 26: 457-494.
7. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C, Henigsberg N, Perez J, Mendlewicz J, Janzing JG, Zobel A, Skibinska M, Kozel D, Stamp AS, Bajs M, Placentino A, Barreto M, McGuffin P, Aitchison KJ: Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008; 38: 289-300.
8. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804-814.
9. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164: 1530-1538.
10. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW: Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR * D study. Arch Gen Psychiatry 2007; 64: 689-697.
11. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: Association of GRIK4 with outcome of antidepressant treatment in the STAR * D cohort. Am J Psychiatry 2007; 164: 1181-1188.
12. Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, Fava M, Rush AJ, Smoller JW: Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR( * )D study. Neuropsychopharmacology 2008; 33: 2810-2819.
13. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S: The FKBP5-gene in depression and treatment response - an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR * D) Cohort. Biol Psychiatry 2008; 63: 1103-1110.
14. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Sourey D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I: Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9: 225-233.
15. Bauer M, Grof P, Müller-Oerlinghausen B (eds): Lithium in Neuropsychiatry: The Comprehensive Guide. London, Informa Healthcare, 2006.
16. Perlis RH, Smoller JW, Ferreira MAR, Mc- Quillin A, Bass N, Chir MB, Lawrence J, Sachs GS, Nimgaonkar V, Scolnick EM, Gurling H, Sklar P, Purcell S: A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009; 166: 718-725.
17. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nöthen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Höfels S, Propping P, Satagopan J, Detera- Wadleigh SD, Hardy J, McMahon FJ: A genome- wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13: 197-207.
18. Rietschel M, Kennedy JL, Macciardi F, Meltzer HY: Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophr Res 1999; 37: 191-196.
19. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, Mc- Creadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D 3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
20. Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-796.
21. Correll CU, Malhotra AK: Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004: 477-489.
22. Malhotra AK, Lencz T, Correll CU, Kane JM: Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 2007; 19: 523-530.
23. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF: A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 2009; 107: 13-21.
24. Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB: Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009; 17: 946-957.
25. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O'Donovan C, Alda M: Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002; 63: 942-947.
26. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly- Harrington NA, Nierenberg AA, Sachs GS, Thase ME: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163: 217-224.
27. Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, Duffy A, O'Donovan C, Teehan A, Alda M: Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007; 104: 185-190.
28. Passmore MJ, Garnham J, Duffy A, Mac- Dougall M, Munro A, Slaney C, Teehan A, Alda M: Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003; 5: 110-114.
29. Hajek T, Hahn M, Slaney C, Garnham J, Green J, Ruzickova M, Zvolsky P, Alda M: Rapid cycling bipolar disorders in primary and tertiary-care treated patients. Bipolar Disord 2008; 10: 495-502.
30. Purcell S, Cherny SS, Sham PC: Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-150.